Form 4: Catalyst Pharmaceuticals Executive Reports Stock Transactions
SEC Form 4 Filing
Chief Commercial Officer Jeffrey Del Carmen reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On December 27, 2024, Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, reported transactions involving the company's stock.
- These transactions included the vesting of 8,667 restricted stock units (RSUs) and the withholding of 3,839 shares to cover applicable taxes.
- Following these transactions, Del Carmen directly owns 22,881 shares of Catalyst Pharmaceuticals common stock and 941,675 restricted stock units.
- The vesting of the RSUs occurred according to a pre-determined schedule, with the second tranche vesting on December 27, 2024.
Sentiment
Score: 5
Explanation: This is a neutral reporting of stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity holdings and transactions of key personnel.
Stakeholder Impact
- The vesting of RSUs and subsequent tax withholding may have a minor dilutive effect on existing shareholders.
- The transactions provide transparency to shareholders regarding executive compensation.
Key Dates
| Date | Description |
|---|---|
| 12/27/2023 | First tranche of restricted stock units vested. |
| 12/27/2024 | Second tranche of restricted stock units vested; shares delivered. |
| 12/27/2025 | Final tranche of restricted stock units scheduled to vest. |
| 12/31/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.